New study reaffirms no link between Tylenol use in pregnancy and autism

Study Findings

The recent study published in JAMA Internal Medicine analyzed electronic health records from over 700,000 mother-child pairs in Hong Kong from 2001 to 2023. It specifically focused on the usage of acetaminophen—commonly sold as Tylenol during pregnancy—and its potential link to autism. The results showed no significant correlation between in utero exposure to acetaminophen and the subsequent development of autism in children.

Context and Controversy

This finding comes in the wake of statements made by former President Trump and Health Secretary Robert F. Kennedy Jr., who claimed in September that acetaminophen use during pregnancy could cause autism. Their claims received significant media attention, prompting public concern and actions such as a lawsuit against Tylenol's maker by Texas authorities.

Response from Medical Community

The medical community has largely refuted the claims made by Trump and Kennedy, reiterating that acetaminophen is considered a safe option for managing pain and fever during pregnancy. Health organizations have warned that untreated fevers during pregnancy pose greater risks including autism, miscarriage, and birth defects.

Impact on Public Perception

Despite the scientific evidence supporting the safety of acetaminophen, fears following the public statements led to a notable decrease in its use among pregnant patients in emergency departments, as reported in a prior Lancet study. This decrease highlights the potential for misinformation to influence public health behaviors and access to safe medications.